Table 1 Baseline characteristics of patients with IBD and other inflammatory bowel diseases.

From: PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to vedolizumab

 

IBD (n = 9)

Other inflammatory diseases (n = 10)

CD (n = 5)

UC(n = 4)

BD (n = 5)

ITB (n = 5)

Female, n (%)

2 (40)

1 (25)

2 (40)

3 (60)

Age at diagnosis

32 (16–40)

48.5 (25–53)

34 (30–57)

49 (35–72)

Duration from onset of symptom (months)

5 (0–5)

5.5 (0–11)

3 (2–10)

0 (0–3)

CRP (mg/L)

0.6 (0.2–2)

0.2 (0.1–0.9)

0.4 (0.1–6)

0.2 (0.1–0.2)

Fecal calprotectin (μg/mg)

388 (43.1–566)*

N/A

412 (202–457)*

N/A

MES

–

2 (2–3)

–

–

  1. Variables are shown as median values (range).
  2. IBD inflammatory bowel disease, CD Crohn’s disease, UC ulcerative colitis, BD intestinal Behcet’s disease, ITB intestinal tuberculosis, CRP: C-reactive protein, MES: Mayo endoscopic score, N/A not available.
  3. *2 of the 5 patients had missing value.
Back to article page